Company News
Bacil Pharma Board Approves ₹50 Crore Rights Issue
Board approved ₹50 crore rights issue to raise funds, subject to shareholder and regulatory approvals.
Authorised share capital increased by ₹45 crore to ₹65 crore via 4.5 crore new shares of ₹10 each